Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.
Will MAPS Readouts Turn Around The Psychedelic Industry?
It’s been a tough summer for both the cannabis and psychedelics industries. It’s been causing investors a lot of concern. Is there hope that the
August 23, 2023